Lincocin: Potent Gram-Positive Bacterial Infection Treatment
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.53 | $75.30 (0%) | 🛒 Add to cart |
| 20 | $7.03 | $150.61 $140.56 (7%) | 🛒 Add to cart |
| 30 | $6.33 | $225.91 $189.76 (16%) | 🛒 Add to cart |
| 60 | $4.42 | $451.82 $265.07 (41%) | 🛒 Add to cart |
| 90 | $4.22 | $677.72 $379.52 (44%) | 🛒 Add to cart |
| 120 | $4.02 | $903.63 $481.94 (47%) | 🛒 Add to cart |
| 180 | $3.71 | $1355.45 $668.69 (51%) | 🛒 Add to cart |
| 270 | $3.41 | $2033.17 $921.70 (55%) | 🛒 Add to cart |
| 360 | $3.01
Best per pill | $2710.89 $1084.36 (60%) | 🛒 Add to cart |
Synonyms | |||
Lincocin (lincomycin hydrochloride) is a lincosamide antibiotic indicated for the treatment of serious infections caused by susceptible strains of gram-positive bacteria, particularly in patients who cannot tolerate penicillin antibiotics. It functions by inhibiting bacterial protein synthesis, leading to bacteriostatic action against a range of pathogens. This injectable solution is reserved for severe infections where less potent antimicrobials are inappropriate or ineffective, requiring administration under strict medical supervision due to its spectrum of activity and potential adverse effects.
Features
- Active ingredient: Lincomycin hydrochloride
- Available as a sterile solution for intramuscular or intravenous injection
- Each mL contains lincomycin hydrochloride equivalent to 300 mg lincomycin
- Bacteriostatic activity against susceptible gram-positive organisms
- Demonstrated efficacy against anaerobic bacteria
- Requires prescription and professional administration
Benefits
- Provides effective treatment for serious infections when penicillin antibiotics are contraindicated
- Offers reliable coverage against streptococcal, staphylococcal, and pneumococcal organisms
- Demonstrates consistent activity against anaerobic bacteria including Bacteroides species
- Suitable for patients with hypersensitivity to beta-lactam antibiotics
- Rapid achievement of therapeutic serum concentrations following parenteral administration
- Established clinical profile with decades of documented efficacy in appropriate infections
Common use
Lincocin is primarily employed in the management of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. Its use is typically reserved for situations where penicillin antibiotics are not suitable due to resistance patterns or patient hypersensitivity. Common applications include treatment of septicemia, lower respiratory tract infections, and bone and joint infections. The medication demonstrates particular utility in anaerobic infections, including those caused by Bacteroides fragilis and other anaerobic organisms. Medical professionals select Lincocin based on culture and sensitivity results when the pathogen demonstrates susceptibility to lincomycin.
Dosage and direction
Dosage must be individualized based on the severity of infection and the patient’s clinical status. For serious infections, the usual adult dosage is 600 mg (2 mL) intramuscularly every 24 hours, or 600 mg to 1 gram intravenously every 8 to 12 hours. For more severe infections, these dosages may be increased. For intravenous administration, each gram should be diluted in at least 100 mL of compatible solution and infused over at least one hour. Pediatric dosage is based on weight at 10 mg/kg every 24 hours intramuscularly or 10 to 20 mg/kg daily intravenously in divided doses. Treatment should continue for at least 10 days in beta-hemolytic streptococcal infections to prevent rheumatic fever or glomerulonephritis.
Precautions
Lincocin should be administered with caution to patients with a history of gastrointestinal disease, particularly colitis. Use with extreme care in patients with severe renal or hepatic impairment, as dosage adjustments may be necessary. Periodic monitoring of liver and kidney function is recommended during prolonged therapy. The possibility of antibiotic-associated colitis should be considered in patients who develop diarrhea during or after treatment. Caution is advised when administering to patients with asthma or significant allergies. Superinfections with nonsusceptible organisms may occur and require appropriate therapy.
Contraindications
Lincocin is contraindicated in patients with known hypersensitivity to lincomycin, clindamycin, or any component of the formulation. It should not be used in patients with a history of antibiotic-associated colitis, regional enteritis, or ulcerative colitis. The medication is contraindicated for the treatment of minor bacterial or viral infections where less potentially toxic agents would be appropriate. Concomitant administration with erythromycin is contraindicated due to potential antagonism.
Possible side effect
The most serious adverse reaction associated with Lincocin is Clostridium difficile-associated diarrhea (CDAD), which may range from mild diarrhea to fatal colitis. Gastrointestinal effects including nausea, vomiting, abdominal pain, and diarrhea occur relatively frequently. Hypersensitivity reactions including rash, urticaria, and anaphylaxis have been reported. Hematologic effects such as neutropenia, leukopenia, thrombocytopenia, and agranulocytosis may occur. Local reactions at the injection site including pain, induration, and sterile abscess formation have been observed. Other potential side effects include tinnitus, vertigo, hypotension, and elevated liver enzymes.
Drug interaction
Concurrent use with neuromuscular blocking agents may enhance neuromuscular blockade. Antagonism may occur with erythromycin and other macrolide antibiotics. Lincocin may affect cyclosporine levels, requiring monitoring. Kaolin-pectin preparations may decrease absorption of orally administered lincomycin. The antibiotic may potentiate the effects of warfarin and other oral anticoagulants. Concurrent use with opioid analgesics may increase the risk of severe constipation and ileus.
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing is important to maintain therapeutic serum levels, so healthcare providers should ensure adherence to the prescribed regimen during inpatient treatment.
Overdose
Symptoms of overdose may include severe diarrhea, nausea, vomiting, and abdominal cramps. In cases of significant overdose, neuromuscular blockade may occur. There is no specific antidote for lincomycin overdose. Treatment should be supportive and symptomatic, with particular attention to electrolyte balance and hydration status. Hemodialysis does not effectively remove lincomycin from the circulation. Management should include monitoring for CDAD and appropriate treatment if it develops.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from freezing and excessive heat. The solution should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is discolored or contains precipitate. Once opened, vials should be used promptly and any unused portion discarded according to institutional protocols for hazardous medications.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lincocin is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Patients should not alter their dosage or discontinue treatment without medical guidance.
Reviews
Clinical studies have demonstrated Lincocin’s efficacy in treating serious gram-positive infections, with particular utility in penicillin-allergic patients. Medical literature supports its use in anaerobic infections, though clinicians note the importance of appropriate patient selection due to the CDAD risk. Healthcare providers report satisfactory clinical outcomes when used according to established guidelines, with emphasis on proper dosing and monitoring. The medication remains a valuable option in specific clinical scenarios despite the development of newer antibiotics.